Determination of apovincaminic acid in human plasma by high-performance liquid chromatography

Maya, Manuela T.; Pais, João P.; Araújo, Henrique M.; Morais, José

doi:10.1016/0731-7085(95)01658-9

Cited by 14 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GC methods based on prior derivatization had been used for the determination of AVA in biological samples [28,29]. While determination of AVA by HPLC with ultraviolet detection [30][31][32][33] and LC-MS [34] was more common. However, all these methods suffered from various drawbacks namely sensitivity, long chromatographic run times, large sample volume for processing or a cumbersome extraction procedure, which prevented their use for routine biological sample analysis.…”

Section: Vinpocetinementioning

confidence: 99%

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Xia

Guo

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

Section: Vinpocetinementioning

confidence: 99%

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Xia

Guo

et al. 2010

Journal of Chromatography B

View full text Add to dashboard Cite

“…Although speculative, because vinpocetine has demonstrated an ability to inhibit platelet aggregation and decrease blood viscosity, it may interact with drugs that are designed to do so therapeutically Maya et al (1996) and Vas and Gulyas (2005). Thrombolytics…”

Section: Low-molecular Weight Heparinsmentioning

confidence: 99%

Vinpocetine☆

Willson¹

2015

Reference Module in Biomedical Sciences

View full text Add to dashboard Cite

Elsevier Inc. All rights reserved. Name of the Clinical Form Vinpocetine Related Names Source: EMTREE apovincamin 22 oic acid ethyl ester; apovincaminic acid ethyl ester; ay 27,255; ay 27255; ay27,255; ay27255; cavinton; ceractin; ethyl apovincamate; ethyl apovincaminate; eusenium; rgh 4405; rgh4405; tcv3b; tcv3b; (11aS,11bS)-11a-Ethyl-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthene-10-carboxylic acid ethyl ester; tcv 3b Chemical Names Eburnamenine-14-carboxylic acid, ethyl ester, (3-alpha,16-alpha) CAS Number 42971-09-5 Reference Module in Biomedical Sciences http://dx.

show abstract

“…As a consequence, the maximum concentrations of vinpocetine are too low to monitor (0.5− 1.5 ng/ml) because of inadequate assay sensitivity and great intra-and inter-subject variability. The half-life of vinpocetine is very short, being non-detectable in plasma within 2−3 h [13,14]. In contrast with vinpocetine, its metabolite, apovinvaminic acid, has much greater concentrations (80−120 ng/ml) and for a much longer period of time (6−8 h).…”

Section: Zusammenfassungmentioning

confidence: 99%

Pharmacokinetics and Comparative Bioavailability of Two Vinpocetine Tablet Formulations in Healthy Volunteers by Using the Metabolite Apovincaminic Acid as Pharmacokinetic Parameter

Vlase

Bodiu²,

Leucuţa

2011

Arzneimittelforschung

View full text Add to dashboard Cite

The objective of this study was to evaluate the pharmacokinetics of apovincaminic acid, the main metabolite of vinpocetine ((3alpha, 16alpha) -eburnamenine-14-carboxylic acid ethyl ester, CAS 42971-09-5), and to assess the average bioequivalence of two immediate release formulations of 10 mg vinpocetine tablets in 24 healthy male volunteers. The relative bioavailability of the test (generic) product (Vimpocetina) with respect to the reference product was determined in a single dose, randomized, crossover study. A simple, rapid specific and reliable high performance liquid chromatographic method coupled with mass spectrometry detection has been developed and validated for vinpocetine and apovincaminic acid. However, only the concentrations of the metabolite could be used for bioequivalence determinations because the concentrations of the parent drug were too low to be accurately measured in the biological matrix. The compartmental analysis of the metabolite's appearance-disappearance in blood shows similarity with first-order kinetics of a drug extravascularly administered. The apparent pharmacokinetic constants were determined. The mean values for the Cmax were 49.5 (+/- 16) ng/ml for test and 51.4 (+/- 14) ng/ml for the reference product. The mean values for the AUC0-infinity were 95 (+/- 29) ng/ml x h for test and 96.9 (+/- 26) ng/ml x h for reference, respectively. The 90 % confidence intervals for test/reference mean ratios of the plasma pharmacokinetic variables Cmax and AUC0-infinity lie between 0.83-1.08 and 0.88-1.08, respectively, which is within the conventional bioequivalence range of 80-125 % (Schuirman test). The difference between Tmax of the test and reference products was statistically non-significant (Friedman test). The test product is therefore bioequivalent to the reference product with respect to the rate and extent of apovincaminic acid pharmacokinetics.

show abstract

Determination of apovincaminic acid in human plasma by high-performance liquid chromatography

Cited by 14 publications

References 6 publications

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Determination of vinpocetine and its primary metabolite, apovincaminic acid, in rat plasma by liquid chromatography–tandem mass spectrometry

Vinpocetine☆

Pharmacokinetics and Comparative Bioavailability of Two Vinpocetine Tablet Formulations in Healthy Volunteers by Using the Metabolite Apovincaminic Acid as Pharmacokinetic Parameter

Contact Info

Product

Resources

About